Ten stocks kicked off the trading week boasting high gains, defying a pessimistic market sentiment, as investors took heart from a flurry of fresh company-specific catalysts that boosted buying appetite.
Of the 10, six hit new record highs, while seven belong to the biopharmaceutical industry.
In this article, we spotlight the names that led the charge on Monday and break down the reasons behind their gains.
To come up with the list, we focused exclusively on stocks with a $2 billion market capitalization and 5 million shares in trading volume.
Photo by Tima Miroshnichenko on Pexels
10. Dyne Therapeutics, Inc. (NASDAQ:DYN)
Dyne Therapeutics jumped by 9.47 percent on Monday to finish at $22.20 apiece as investors cheered the encouraging results from its ongoing clinical trial to test the efficacy of therapy candidate, zeleciment rostudirsen, for individuals with Duchenne muscular dystrophy (DMD).
In an update on the same day, Dyne Therapeutics, Inc. (NASDAQ:DYN) said that the drug candidate met its primary endpoint, demonstrating a 5.46 percent increase in muscle-content adjusted dystrophin levels alongside functional improvements across multiple clinical endpoints.
“With its high level of dystrophin expression, favorable safety profile, convenient monthly dosing regimen, and functional improvement as assessed by six prespecified clinical measures, z-rostudirsen has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” said Dyne Therapeutics, Inc. (NASDAQ:DYN) President and CEO John Cox.
Notably, the therapy was considered generally safe and tolerable, with the commonly reported adverse effects being only fever and headache.
The trial enrolled 32 ambulant and non-ambulant males with DMD aged 4 to 16 and had mutations amenable to a method called exon 51 skipping.
The company said it is on track to submit an accelerated approval in the second quarter of 2026, positioning itself to launch the said therapy in the first quarter of 2026.
9. Carvana Co. (NYSE:CVNA)
Carvana soared to a new all-time high on Monday after 10 consecutive days of rally, as investors took heart from its official inclusion in the S&P 500 index.
At intra-day trading, Carvana Co. (NYSE:CVNA) jumped to its highest price of $456.97 before paring gains to end the day just up by 12.06 percent at $447.98 apiece.
This followed the S&P Dow Jones Indices’ report on Friday, adding Carvana Co. (NYSE:CVNA) to the S&P 500 recomposition alongside building materials firm CRH PLC and construction services firm Comfort Systems USA, effective December 22, 2025.
Its inclusion was a significant milestone, having been written off as a “zombie” by Wall Street a few years back.
Share prices of companies added to benchmark indices typically pop as fund managers would need to reposition their portfolios to mirror the composition ahead of the start of their inclusion.
Additionally, the S&P Dow Jones Indices also announced changes to the composition of the S&P MidCap 400 and the S&P SmallCap 600, effective on the same date.
Carvana Co.’s (NYSE:CVNA) rally was supported by the increasing hopes for an interest rate cut, which is set to benefit the company through lower car loans for buyers.
Policymakers are expected to announce on Wednesday, December 10, their decision on interest rates, and economists are highly expecting a 25-basis point rate cut.
8. Warby Parker Inc. (NYSE:WRBY)
Warby Parker rallied by 13.27 percent on Monday to close at $21.26 apiece as investor sentiment was bolstered by the looming launch of its artificial intelligence glasses in partnership with Google.
In a regulatory filing on the same day, Warby Parker Inc. (NYSE:WRBY) said that the AI glasses—the first line of intelligent eyewear, which will incorporate multimodal AI with prescription and non-prescription lenses—are officially launching in 2026.
Warby Parker Inc. (NYSE:WRBY) and Google already announced the said partnership in May this year, under which the latter committed to shell out $75 million for the former’s product development, alongside an optional $75 million investment in the eyewear-maker, subject to the achievement of certain milestones.
Under the partnership, Warby Parker Inc. (NYSE:WRBY) would design and manufacture the said eyewear, to be equipped with Google’s technology ecosystem.
“Since our launch, we’ve set out to transform the optical industry by leveraging pioneering technology to design better products and experiences—and over the past 15 years, we’ve done just that,” said Warby Parker Inc. (NYSE:WRBY) co-Founder and co-CEO Dave Gilboa.
“Looking ahead, we believe multimodal AI is perfectly suited for glasses, enabling real-time context and intelligence to augment a wearer’s surroundings as they move through the world. We couldn’t be more excited to be partnering with Google to bring together the best of AI and the best of eyewear,” he added.
7. Nurix Therapeutics Inc. (NASDAQ:NRIX)
Nurix Therapeutics extended its winning streak to a fourth straight day on Monday, jumping 18.68 percent to finish at $21.47 apiece as investors took heart from the promising results of its clinical trial for bexobrutideg in patients with a rare blood cancer called Waldenström macroglobulinemia.
In an updated report, Nurix Therapeutics Inc. (NASDAQ:NRIX) said that it tested 200mg to 600mg of the therapy candidate on 31 patients aged 49 to 88 years, who have already tested more than several other treatments.
The study showed that bexobrutideg showed an objective response rate of 75 percent, including very good partial responses in three patients, partial responses in 14 patients, and minor responses in four patients. Six patients also had a best response of stable disease.
As of the September 19, 2025, data cut, 15 patients continued on treatment for more than six months, while six patients remained on treatment for more than one year.
Notably, the drug candidate was well tolerated, with adverse events only reported at low grade, with the most common being neutropenia, petechiae, diarrhea, anemia, purpura/contusion, and thrombocytopenia.
“These clinical data and recent data highlighting the unique properties of our potent and highly selective BTK degrader contribute to a growing body of evidence that supports bexobrutideg’s potential to be the best-in-class and an important new therapeutic option for patients,” said Nurix Therapeutics Inc. (NASDAQ:NRIX) President and CEO Arthur Sands.
“We believe bexobrutideg is an innovative therapy with the potential to transform care in CLL (chronic lymphocytic leukemia), WM, and additional NHL (non-Hodgkin lymphoma) indications, while supporting long-term value creation as its development expands into inflammatory and autoimmune settings,” he added.
6. Ocular Therapeutix, Inc. (NASDAQ:OCUL)
Ocular Therapeutix surged to a new four-year high on Monday after rallying for four consecutive days, with investor sentiment bolstered by announcements that it would officially submit a new drug application (NDA) for Axpaxli for the treatment of wet age-related macular degeneration (AMD).
At intra-day trading, the stock soared to its highest price of $16.44 before trimming a few cents to end the day just up by 28.06 percent at $16.11 apiece.
In a statement on Monday, Ocular Therapeutix, Inc. (NASDAQ:OCUL) said that it would submit the NDA shortly, assuming it generates positive results from the one-year data of its SOL-1 clinical trial to test the efficacy of Axpaxli.
Historically, the FDA requires two adequate and well-controlled clinical trials to demonstrate the safety and efficacy of ophthalmic product candidates, particularly for larger indications of use such as wet AMD.
However, recent statements indicate that the agency would now move to requiring just a single registration trial for approval, as long as the study was adequately powered and controlled.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) said that it expects additional data from the second year of the SOL-1 clinical trial—to be called SOL-R and SOL-X—to help clinicians and payors appreciate the anticipated benefits of Axpaxli’s efficacy, safety, and durability.
“The company will engage further with the FDA regarding next steps on the regulatory pathway for AXPAXLI and will provide updates as appropriate,” it said.
5. Confluent Inc. (NASDAQ:CFLT)
Confluent snapped a two-day losing streak on Monday, soaring 29.08 percent to finish at $29.87 apiece as investors repositioned portfolios following IBM’s announcement that it would acquire the company for $11 billion.
In a statement, IBM said that it officially entered into a definitive agreement with Confluent Inc. (NASDAQ:CFLT) under which the former would acquire all of the latter’s outstanding common shares at a price of $31 apiece.
IBM said the total value will be entirely financed with available cash on hand.
The transaction has already been approved by both firms’ board of directors, as well as Confluent Inc.’s (NASDAQ:CFLT) largest shareholders, who hold a combined 62 percent of the company.
The transaction is expected to close in the middle of 2026, subject to customary closing conditions, including the minority shareholders and other regulatory approvals.
“IBM and Confluent together will enable enterprises to deploy generative and agentic AI better and faster by providing trusted communication and data flow between environments, applications and APIs. Data is spread across public and private clouds, datacenters and countless technology providers,” IBM Chairman, President, and CEO Arvind Krishna.
“With the acquisition of Confluent, IBM will provide the smart data platform for enterprise IT, purpose-built for AI,” he noted.
4. Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Terns soared to a new all-time high on Monday as investors took heart from the encouraging results of its clinical trial to test the efficacy of drug candidate, TERN-701, in patients with previously treated chronic myeloid leukemia (CML).
At intra-day trading, the stock climbed to its highest price of $45 before trimming gains to finish the session just up by 37.02 percent at $40.23 apiece.
In an updated report, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) said that its recent clinical trial for TERN-701 recorded a 64 percent major molecular response rate (MMR) in 63 enrolled patients who took the drug candidate for 24 weeks.
Additionally, it also saw a 74 percent MMR at higher doses of 320 mg.
Of the total enrollees, only 55 patients remained on treatment, as four dropped out due to disease progression.
Meanwhile, three stopped due to the physician and patient’s decision, while one stopped after experiencing adverse effects.
Following the results, Terns Pharmaceuticals, Inc. (NASDAQ:TERN) received a 107 percent price target upgrade of $58 from investment firm Oppenheimer, versus the $28 previously. It also maintained its “outperform” rating on the stock.
Oppenheimer said that the company’s update supports a potential “best-in-class profile” for the TERN-701 in the CML market.
3. Kymera Therapeutics, Inc. (NASDAQ:KYMR)
Kymera Therapeutics soared to a new all-time high on Monday after rallying for four consecutive days, as investor sentiment was boosted by the stellar results of its clinical trial to test the efficacy of KT-621 in patients with moderate to severe eczema.
At intra-day trading, the stock soared to its highest price of $103 before trimming gains to end the day just up by 41.55 percent at $94.30 apiece.
According to Kymera Therapeutics, Inc. (NASDAQ:KYMR), it tested KT-621 on 22 enrolled patients for four weeks and nearly eliminated by 98 percent and 94 percent a transcription factor called STAT6, which fuels allergic inflammation in both blood and skin, respectively.
In other news, Kymera Therapeutics, Inc. (NASDAQ:KYMR) announced plans to raise $500 million from the issuance of new shares, with the potential to increase the size to $575 million.
The company said that proceeds from the offer will be used to finance its ongoing pipeline of preclinical and clinical degrader programs, while the balance will be used for working capital and other general corporate purposes.
In line with the offer, Kymera Therapeutics, Inc. (NASDAQ:KYMR) granted its underwriters an option to purchase an additional $75 million at the public offer price.
2. Structure Therapeutics Inc. (NASDAQ:GPCR)
Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate, aleniglipron, in obese patients with co-morbidity.
At intra-day trading, the stock surged to its highest price of $94.90 before profit-taking persisted and trimmed its gains to end the day just up by 102.49 percent at $69.98 apiece.
This followed news that patients who took a 120mg dose once daily achieved an 11.3 percent weight loss at 36 weeks, while those who took 240mg reduced weight by up to 15.3 percent in the same period.
Aleniglipron demonstrated a tolerability profile consistent with the GLP-1 receptor agonist class and a compelling off-target safety profile.
Following the results, Structure Therapeutics Inc. (NASDAQ:GPCR) expects to move forward with the third phase of the clinical trial in the middle of 2026.
Before the third phase, it plans to sit down with the Food and Drug Administration in the first half of next year to finalize the phase 3 design, which is currently targeted with a starting titration dose of 2.5 mg with the intent to evaluate multiple doses up to 240 mg.
“These findings provide comprehensive information to move into Phase 3 development and reinforce aleniglipron’s potential to become a backbone oral small molecule therapy for obesity—one that is accessible, scalable, and combinable,” said Structure Therapeutics Inc. (NASDAQ:GPCR) CEO Raymond Stevens.
1. Wave Life Sciences Ltd (NASDAQ:WVE)
Wave Life hit a new six-year high on Monday after soaring by more than double following stellar results from the first phase of its obesity drug clinical trial.
At intra-day trading, the stock climbed to its highest price of $19.54 before trimming gains to finish the day just up by 147.26 percent at $18.52 apiece.
In an updated report, Wave Life Sciences Ltd (NASDAQ:WVE) said that enrolled patients who took 240 mg of its drug candidate, WVE-007, improved their body composition through a 4.5 percent total fat loss, 9.4 percent visceral fat reduction, and a 3.2 percent increase in lean mass in just three months.
Notably, the drug candidate taken up to 600 mg was generally safe and well-tolerated, and there were no serious adverse events recorded.
Wave Life Sciences Ltd (NASDAQ:WVE) expects to deliver the results of the second round of the clinical trial, covering six months for the 240 mg single-dose cohort, as well as three-month follow-up data for the 400mg single-dose cohort.
In the second quarter of 2026, the company is also targeting to deliver six-month follow-up data from the 400 mg single-dose cohort and three-month follow-up data from the 600 mg single-dose cohort.
For phase 2, Wave Life Sciences Ltd (NASDAQ:WVE) would evaluate WVE-007 as both a monotherapy and an add-on therapy to incretins in populations with higher BMI and related co-morbidities, and as a maintenance therapy post-incretin treatment.
While we acknowledge the potential of WVE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than WVE and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
